

Annual General Meeting 2007

bioMD Limited

Innovative Biomedical
Devices and Technologies


bioMD
LIMITED

Annual General Meeting 2007

AGENDA

WELCOME

Mr Robert Scott, Chairman of the Board

CHAIRMAN'S ADDRESS

RESOLUTIONS

- 1) Adopt the Remuneration Report for the Year Ended 30 June 2007
- 2) Re-election of Director, Mr Robert Scott

MANAGING DIRECTOR'S ADDRESS

Mr Michael Bennett

Annual General Meeting 2007

Company Highlights

- ▶ 3 Pre-clinical Trials successfully completed;
- ▶ Ethics Approval received for a Phase II Human Clinical Trial of cardiovascular patches treated with the ADAPT Tissue Processing Technology;
- ▶ Presentation at “The Society for Heart Valve Disease” 4th Biennial Meeting in New York by Celxcel’s Chief Scientific Officer, Dr Leon Neethling.

Annual General Meeting 2007

ADAPT®

Pre-Clinical Studies 2006/07

- ▶ ADAPT Treated Bovine Pericardial Tissue Patches in the Jugular Position *Completed*
- ▶ ADAPT Treated Kangaroo and Bovine Pericardial Tissue Patches and Kangaroo Carotid Artery Grafts *Completed*
- ▶ Comparison of ADAPT Treated Bovine Pericardial Patch with two commercially available biomaterial patches. *Completed*

Annual General Meeting 2007

PHASE II HUMAN CLINICAL TRIAL


- ▶ CARDIOCEL Bioimplant Tissue Patch (ADAPT treated bovine pericardium)
- ▶ Trial to be conducted at Universitas Hospital, Bloemfontein, South Africa
- ▶ Ethics Committee approval granted - University of the Free State, Bloemfontein
- ▶ Department of Health (South Africa) trial registration number received



Annual General Meeting 2007

PHASE II HUMAN CLINICAL TRIAL

- ▶ CARDIOCEL – a bioimplant tissue using ADAPT Tissue Processing Technology for the repair of heart defects in open-heart surgery, e.g. “hole in the heart” procedures
- ▶ 50 patient trial
- ▶ CARDIOCEL bioimplants will be implanted over a 12 month period
- ▶ Post-operative 12 month follow up for each patient



Annual General Meeting 2007

PATCH MANUFACTURING

- ▶ Agreement signed with The Ray & Bill Dobney Cell Tissue Therapies WA manufacturing unit at Royal Perth Hospital



- ▶ TGA Certified GMP clean room facility

Annual General Meeting 2007

PATCH MANUFACTURING



**PHASE II HUMAN
CLINICAL TRIAL**

BIOCOMPATIBILITY TESTING

Manufacture of patches
for independent testing,
giving FDA approved
certificate

Annual General Meeting 2007

THE WAY FORWARD

We are here



Animal Trials

Human Trials

Commercialisation

**Manufacturing
facility**


Packaging

**TGA / CE / FDA
Approval**

**Sign
Licence /
Co-development
Agreement**

Presentation at SHVD

“Enhanced Durability and Biocompatibility of Decellularised Bovine Pericardium, Crosslinked with an Ultra Low Concentration Monomeric Aldehyde and treated with ADAPT®”



- ▶ Presentation at “The Society for Heart Valve Disease” 4th Biennial Meeting in New York;
- ▶ Presented by Celxcel’s Chief Scientific Officer, Dr Leon Neethling;
- ▶ Worldwide market response.

ADAPT[®]


Emerging Technologies

- ▶ Minimally invasive (keyhole) heart valve replacements
- ▶ Patent Foramen Ovale's (PFO) Heart Defects
- ▶ Using Matrix to deliver “growth factors” and “stem cells”

Annual General Meeting 2007


ADAPT[®]

ADAPT Tissue Processing Technology can be used to process bioimplants that can be used in 5 surgical specialties



Annual General Meeting 2007

ADAPT®



Forecast 2011 = US\$1.5 billion

Global Medical Device Companies

Multi-specialty 1st Tier

- Johnson & Johnson
- Boston Scientific
- Bard / Davol
- Covidien

2nd Tier

- Atrium, etc.

Annual General Meeting 2007




CSIRO

Adult IV Sites

Collaborative Research Agreement

- ▶ Research completed in the Materials Robustness Phase (Stage II Phase 2)
- ▶ Research commenced in the revised statement of work for Stage III
- ▶ Provisional patent application lodged in USA



- Internal Jugular
- Subclavian
- Peripheral
- Femoral
- Saphenous Cutdown

bioMD
LIMITED

Intellectual Property

CSIRO Catheter Material

- ▶ 1 Patent application in progress

ADAPT Tissue Processing Technology

- ▶ 1 Patent granted
- ▶ 16 Patents pending
- ▶ 5 Patent applications

The Year Ahead

- ▶ **Global Partnering for the ADAPT Tissue Processing Technology**
 - ▶ Co-product development
 - ▶ Co-marketing
 - ▶ Licensing
- ▶ **TGA Certification for ADAPT[®] Tissue Processing Technology**
- ▶ **CSIRO – Final stage of R&D collaboration**

Annual General Meeting 2007

Quality Assurance



**bioMD has Quality Assurance
Accreditation to AS9001:2000**

Our QA System also meets the requirements of AS13485 which specifically covers the manufacture of Medical Devices.

Annual General Meeting 2007

bioMD at a glance...

Listed on Australian Stock Exchange - 24 March 2004



Market Capitalisation @ 31/10/07	\$10.12 million
Fully Paid Ordinary Shares	84.3 million
Top 50 Shareholders	73.6%
Group Cash position @ 31/10/07	\$1.9 million
Group Average Cash Burn	\$70,000 per month

For all the latest news and updates visit:

www.biomd.com.au

